Education and Training
FT819 in Subjects With B-cell Malignancies
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: FT819
- drug: Cyclophosphamide
- drug: Fludarabine
- drug: IL-2
- drug: Bendamustine
Eligibility
Key Inclusion Criteria:
Diagnosis of B-cell lymphoma, CLL or B-ALL as described below:
B-Cell Lymphoma:
- Histologically documented lymphomas expected to express CD19
- Relapsed/refractory disease following at least 2 prior lines of multi-agent
immunochemotherapy
Chronic Lymphocytic Leukemia (CLL):
- Diagnosis of CLL per iwCLL guidelines
- Relapsed/refractory disease following at least two prior systemic treatment regimens
Precursor B-cell Acute Lymphocytic Leukemia (B-ALL):
- Diagnosis of B-ALL by flow cytometry, bone marrow histology, and/or cytogenetics
- Relapsed/refractory disease after at least 2 cycles of standard multiagent induction
chemotherapy. For subjects with Philadelphia-chromosome positive (Ph+) disease,
failure or intolerance to a tyrosine kinase inhibitor therapy-containing regimen
ALL SUBJECTS:
- Capable of giving signed informed consent
- Age ≥ 18 years old
- Stated willingness to comply with study procedures and duration
- Contraceptive use for women and men as defined in the protocol
Key Exclusion Criteria:
ALL SUBJECTS:
- Females who are pregnant or breastfeeding
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≥2
- Body weight <50 kg
- Evidence of insufficient organ function
- Receipt of therapy within 2 weeks prior to Day 1 or five half-lives, whichever is
shorter; or any investigational therapy within 28 days prior to Day 1
- Currently receiving or likely to require systemic immunosuppressive therapy
- Ongoing requirement for systemic GvHD therapy following prior allogeneic hematopoietic
stem cell transplant (HSCT) or allogeneic CAR-T
- Receipt of an allograft organ transplant
- Known active central nervous system (CNS) involvement by malignancy
- Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or
neurodegenerative disease
- Clinically significant cardiovascular disease
- Positive serologic test results for HIV infection
- Positive serologic and polymerase chain reaction (PCR) test results for Hepatitis B
(HBV) infection
- Positive serologic and PCR test results for Hepatitis C (HCV) infection
- Live vaccine <6 weeks prior to start of lympho-conditioning
- Known allergy to albumin (human) or DMSO
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Maria Iglesias
+1 650-723-4247
I'm interested